MICHAEL BAUGUESS: Open Payments
NPI 1912986647 · OROVILLE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,133 in 130 payments from 25 companies in 2025. Trend: 2023 $3,791 · 2024 $4,814 · 2025 $4,133
Food & beverage: $4,133
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 24 | $944 |
| ViiV Healthcare Company | 17 | $388 |
| Merck Sharp & Dohme LLC | 11 | $379 |
| Novo Nordisk Inc | 7 | $288 |
| Amgen Inc. | 9 | $267 |
| Vanda Pharmaceuticals Inc. | 3 | $220 |
| PFIZER INC. | 8 | $177 |
| Braeburn Inc. | 11 | $165 |
| ABBVIE INC. | 5 | $153 |
| AstraZeneca Pharmaceuticals LP | 3 | $148 |
Products named: PIFELTRO, FANAPT, NURTEC ODT, DOVATO, APRETUDE, BRIXADI, Ozempic, MAVYRET.
Industry payments across CA — which companies pay providers there.
